The Clinical Research Program and the Treatment Research Operations Program of DAIDS conduct clinical trials to evaluate potentially effective therapeutic interventions against HIV infection and its sequelae. These trials are conducted through an academic-based consortium of medical institutions called the AIDS Clinical Trials Group (ACTG), as well as a community-based consortium called the Community Programs for Clinical Research on AIDS (CPCRA). The purpose of this contract will be to provide DAIDS with a third clinical trials mechanism, separate and distinct from both the ACTG and the CPCRA, which will enable DAIDS to rapidly address critical questions about therapeutic agents or innovative intervention approaches and to evaluate potentially effective therapies, which may fall outside the immediate priorities of the existing consortia. This contract specifically will not replicate the structure, functions, or research conducted through the ACTG and CPCRA systems; rather, it is expected to complement those important research activities. The contractor will provide personnel, materials, equipment and facilities to accomplish the following tasks: a. Provision of medical and statistical expertise for study design and interpretation b. Protocol development and review c. Provision of clinical trial sites and laboratory services d. Provision of an investigational drug repository and distribution service e. Site monitoring, site registration, preparation of INDs and other tasks required for regulatory compliance f. Provision of a biospecimen repository g. Implementation of clinical trials h. Data management and analysis services

Project Start
1991-09-27
Project End
1996-09-26
Budget Start
1993-06-17
Budget End
1994-09-26
Support Year
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Westat, Inc.
Department
Type
DUNS #
City
Rockville
State
MD
Country
United States
Zip Code
20850
Wahl, Sharon M; Redford, Maryann; Christensen, Shawna et al. (2011) Systemic and mucosal differences in HIV burden, immune, and therapeutic responses. J Acquir Immune Defic Syndr 56:401-11
Cohn, Jonathan A; Hashemi, Farhad B; Camarca, Margaret et al. (2005) HIV-inducing factor in cervicovaginal secretions is associated with bacterial vaginosis in HIV-1-infected women. J Acquir Immune Defic Syndr 39:340-6
Lurain, Nell S; Robert, Emmanuel S; Xu, Jiahong et al. (2004) HIV type 1 and cytomegalovirus coinfection in the female genital tract. J Infect Dis 190:619-23
Nag, Pratip; Kim, Jenney; Sapiega, Vytautas et al. (2004) Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis 190:1970-8
Kovacs, A; Wasserman, S S; Burns, D et al. (2001) Determinants of HIV-1 shedding in the genital tract of women. Lancet 358:1593-601
Hafner, R; Bethel, J; Standiford, H C et al. (2001) Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. Antimicrob Agents Chemother 45:1572-7
Landay, A L; Bethel, J; Schnittman, S (1998) Phenotypic variability of lymphocyte populations in peripheral blood and lymph nodes from HIV-infected individuals and the impact of antiretroviral therapy. DATRI 003 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retroviruses 14:445-51
Hafner, R; Bethel, J; Power, M et al. (1998) Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 42:631-9
Bartlett, J A; Wasserman, S S; Hicks, C B et al. (1998) Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. AIDS 12:1291-300
Lieberman, J; Fabry, J A; Fong, D M et al. (1997) Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocytes response to HIV type 1 in an infected individual. AIDS Res Hum Retroviruses 13:383-92

Showing the most recent 10 out of 13 publications